• 제목/요약/키워드: Hepatitis A virus (HAV)

검색결과 46건 처리시간 0.02초

Analyze of Hepatitis A Virus Genotypes in Eastern Area of Jeonnam, Korea

  • Seo, Min-Young;Lee, Hyeok-Jae;Han, Weon-Dong
    • 대한의생명과학회지
    • /
    • 제17권1호
    • /
    • pp.27-37
    • /
    • 2011
  • Hepatitis A virus (HAV) is a causative agent of triggering acute hepatitis which is transmitted by person-to-person contact and or fecal-oral route. In previous studies, most hepatitis A virus (HAV) isolates had been genotype IA in Korea. Recently, a small number of different genotypes were reported with an upsurge of acute hepatitis by HAV. Therefore, the distribution of HAV genotypes was investigated. RNA was extracted from anti-HAV IgM positive sera which were collected from February to August 2009, at a tertiary care hospital in eastern Jeonnam, Korea. Nested reverse transcription PCR and direct sequencing for VP1/P2A region of the HAV were performed. A total of 365 cases with suspected acute hepatitis were tested for anti-HAV IgM and positive results were obtained in 24 sera (9.0%), which were collected 2 to 15 days (median, 7 days) after the onset of symptoms. Of the 24 seropositive samples, 14 (58.3%) samples were positive for HAV RNA, among which 4 isolates (28.6%) were genotype IA and the other 10 (71.4%) were genotype IIIA. Both IA and IIIA genotypes were isolated from 5~6 neighboring administrative districts throughout the year without geographic or seasonal restrictions. HAV genotypes (IA and IIIA) were observed from the eastern Jeonnam for the studied.

바이러스 불활화 공정에 대한 Hepatitis A Virus와 Murine Encephalomyocarditis Virus의 민감도 비교 (Comparative Inactivation of Hepatitis A Virus and Murine Encephalomyocarditis Virus to Various Inactivation Processes)

  • 김인섭
    • 미생물학회지
    • /
    • 제39권4호
    • /
    • pp.242-247
    • /
    • 2003
  • Murine encephalomyocarditis virus (EMCV)는 혈장유래의약품의 바이러스 안전성 검증을 위해 hepatitis A virus (HAV)의 모델 바이러스로 사용되어왔다. 근래에 혈액응고인자제제에 의한 HAV 감염사례가 보고되면서 혈장유래의약품의 HAV 안전성 검증에 대한 국제적인 규제가 강화되어가고 있다. 본 연구에서는 HAV와 EMCV의 바이러스 불활화 공정에 대한 민감도를 평가하여, 혈장유래의약품 제조공정에서 HAV 불활화 공정의 검증법을 표준화하고자 하였다. HAV와 EMCV의 바이러스 불활화 공정에 대한 민감도를 평가한 결과 HAV가 60$^{\circ}C$ 열처리, low pH 처리(pH 3.9), 0.1 M NaOH 처리, 동결건조 공정 모두에서 EMCV보다 더 저항성이 큰 것을 확인할 수 있었다. EMCV는 특히 열처리와 0.1 NaOH 처리에 민감하게 불활화 되었지만, HAV는 큰 저항성을 나타내었다. 열처리의 경우 2시간 안에 EMCV는 검출한계 이하로 감소하였지만, HAV는 5시간 후에 검출한계 이하로 감소하였다. 0.1 M NaOH 처리시 EMCV는 15분 안에 검출한계 이하로 감소하였지만, HAV는 120분 정도의 처리에도 감염성 바이러스가 검출되었다. pH 3.9에서 25$^{\circ}C$로 14일 동안 항온하였을 때 HAV와 EMCV의 log 감소인수는 각각 1.63, 3.84이었다. 또한 혈액응고 8인자 제조공정의 동결건조 과정에서 HAV와 EMCV의 log 감소인수는 각각 1.21, 4.57이었다. 이와 같은 결과는 혈장유래의약품 제조공정의 HAV 불활화 또는 제거 검증시 모델 바이러스로 사용된 EMCV의 검증 결과를 해석함에 있어 보다 신중함을 가져야 한다는 것을 보여준다. 또한 보다 정확한 HAV검증 결과를 얻고자 한다면 모델 바이러스인 EMCV 보다 HAV를 사용하는 것이 보다 더 타당하다고 사료된다.

사업장 보건관리에 따른 A형, B형 간염 항체 양성률 (Seroprevalence of Hepatitis A and B Virus Antibody of Employees among Three Companies with Different Health Policy)

  • 고현민;손준석
    • 한국산업보건학회지
    • /
    • 제25권2호
    • /
    • pp.229-235
    • /
    • 2015
  • Objectives: We checked hepatitis A virus antibody(anti-HAV IgG) and hepatitis B virus antibody(HBsAb) in three large companies. The result could be a guideline to establish proper health policy for Hepatitis A and B virus preventive plan in company. Methods: We investigated the seroprevalence of anti-HAV IgG and HBsAb, and demographic characteristics of employee volunteer in three companies in southern area of Korea. Company was divided three according to health policy for hepatitis A and B. Results: The seroprevalence rate of anti-HAV IgG in company A, B, and C was 53.6%, 25.8%, and 17.7%(P<0.001), respectively. The seroprevalence rate of HBsAb in workplace A, B, and C was 79.7%, 82.4%, and 70.9%(P<0.001), respectively. Anti-HAV IgG showed more considerable difference among the companies. Conclusions: The results confirmed that low rate of IgG anti-HAV and HBsAb, particularly in the company that had low level of hepatitis education and vaccination program. This study was important for establishing hepatitis education policies, to prevent and control outbreaks in companies.

황달을 동반한 급성 A형 간염 환자 3예의 변증 분형과 인진(茵蔯)의 응용 치료 (Disease Pattern Identification in Oriental Medicine and Herb Medicine treatment for Acute Hepatitis A with Jaundice : Case Series of 3 Patients)

  • 김동웅
    • 동의생리병리학회지
    • /
    • 제24권4호
    • /
    • pp.696-701
    • /
    • 2010
  • Hepatitis A is acute hepatitis caused by the hepatitis A virus (HAV), HAV is a non-enveloped 27nm, heat-, acid, and ether-resistant RNA virus in the Picornavirus family. HAV is transmitted primarily through fecal-oral route and the incidence rate of hepatitis A is closely related to environmental hygiene and socioeconomic condition. Recent improvements in sanitation, public health policies, and socioeconomic development in South Korea have had great impact on the incidence of hepatitis A, which natural production of antibodies against HAV and the prevalence of HAV antibody has decreased. However, during the past ten years, symptomatic HAV infection substantially increased among juveniles and young adults in their twenties and thirties, and hepatitis A has become one of the most common acute hepatitis. Though there has been no report on treatment of hepatitis A with jaundice by oriental medicine in South Korea, many studies and case reports on treatment of icteric hepatitis of which main symptom is jaundice have been published in other countries. To treat patients diagnosed with hepatitis or suspected cases in oriental medicine hospitals, we need to have concerned about hepatitis A. This report is disease pattern identification in oriental medicine and treatments of 3 patients who were diagnosed with acute hepatitis A and treated in oriental medicine hospital.

Prevalence of Antibody for Hepatitis A Virus among Hospital Workers

  • Cho, Byung-Chul;Park, Bok-Ja;Kim, Yoo-Hyun
    • 대한임상검사과학회지
    • /
    • 제44권1호
    • /
    • pp.1-6
    • /
    • 2012
  • Hepatitis A virus (HAV) is an epidemiologically important virus with a worldwide distribution. It causes acute hepatitis in humans. HAV infection is often subclinical or asymptomatic in children; however, symptomatic acute infections become more common with age. In this study, we investigated the prevalence of anti-HAV among hospital workers in Jeonbuk province. 447 (127 males, 320 females) persons were included in the study from January to June, 2011. Anti-HAV (total and IgM) in the sample serum was measured by VIDAS Hepatitis A (bioMerieux, France), and IgM positive samples were tested in terms of their serum alanine aminotransferase (ALT) levels by a HITACHI 7600-010 automatic analyzer (HITACHI, Japan). The overall prevalence of total anti-HAV was 45.9% (205/447), and rate for males (60.6%) was higher than that for females (40%). According to the age group, the prevalence rates of total anti-HAV were 20% (1/5) in those under 20 years old, 11.3% (18/160) in those 20-29 years, 49.7% (71/143) in those 30-39 years, 86.5% (83/96) in those 40-49 years, 92.9% (26/28) in those 50-59 years, and 40% (6/15) in those over 60 years old. The total prevalence of anti-HAV IgM was 0.8% (4/447), and rate for males (1.6%) was higher than that for females (0.6%). Through this study, we determined the prevalence of anti-HAV among hospital workers in Jeonbuk province. The prevalence of the HAV antibody overall was low in hospital workers under 40 years old and in those over 60 years old. Therefore, an improvement in sanitary conditions and hygiene and vaccinations against HAV in this population are recommended.

  • PDF

IMS-RT-PCR을 활용한 육성돈 분변으로부터 간염 A형 바이러스의 신속순수분리 및 검출법 연구 (Use of IMS-RT-PCR for the Rapid Isolation and Detection of Hepatitis A Virus from the Swine Feces)

  • 이희민;김두운
    • 한국식품과학회지
    • /
    • 제44권5호
    • /
    • pp.638-642
    • /
    • 2012
  • 돼지축사에서 채집해온 6개의 육성돈의 분변에서 식중독 유발 바이러스인 HAV와 HEV를 검출하였으며, HAV는 88.3%의 검출율을 보였으며, HEV는 33.3%의 검출율을 보였다. 결과에는 제시하지 않았으나, 염기서열 분석결과 HEV는 사람에게 전염이 가능한 유전자형인 III형이었으며, 실험적으로 사람의 간세포인 PLC/PRF/5에 접종하였을 때 증식이 됨을 확인하였다. 식중독 유발 바이러스인 HAV와 HEV는 오염된 식품이나 물을 섭취하거나 교차 오염에 의해 전염이 가능하기 때문에 돼지축사에서 위생상태의 개선뿐만 아니라 육류를 섭취하기 전인 운송 및 가공과정까지 식중독 유발 바이러스에 의한 교차오염을 막는 노력이 필요하다. HAV와 HEV 모두 검출된 분변에서 HAV를 순수분리하고 빠르게 검출하기 위해 IMS-RT-PCR을 적용하였으며, 항원-항체 반응에 의해 순수하게 HAV만을 분리할 수 있었다. 또한 HAV만이 순수분리 되었는지 재확인하기위해 세포감염을 통해 증식된 바이러스를 확보한 후 nested RT-PCR을 수행한 결과, HAV만을 순수 분리할 수 있음을 확인하였다. 이는 IMS 활용기술이 단순히 항체를 교체함으로써 다른 특정 식중독 유발 바이러스의 다양한 시료에서 바이러스 순수분리 및 검출에 활용 가능성이 있음을 확인하였다.

한국 소아 A형 간염 현황 (Current status of hepatitis A virus infections in Korea)

  • 윤희상
    • Clinical and Experimental Pediatrics
    • /
    • 제51권7호
    • /
    • pp.690-695
    • /
    • 2008
  • The age-specific anti-hepatitis A virus (HAV) seroprevalence rates in South Korea have changed markedly since the last 2030 years with an improvement in the socio-economic, housing, and environmental-sanitation conditions. These changes are characterized by very low anti-HAV seropositive rates among individuals less than 30 years of age; however, nowadays, most adolescents and young adults at an increased risk of developing symptomatic HAV infections. The Korea Center for Disease Control Sentinel Surveillance System has recently revealed an increase in the incidence of hepatitis A infection since 2001 and has revealed a potential endemic nature of the hepatitis A infection. Hepatitis A vaccines that were introduced in 1997 in Korea have made the current anti-HAV IgG positive rates in children (less than 10 years of age) approximately 50% of the rates observed in Seoul in 2006. However, in the same year, a few children were diagnosed as having anti-HAV IgG antibodies in Busan. This suggests the presence of some difference in the vaccination policy among doctors practicing in Seoul and Busan. Thus, the current recommendation of vaccinating 12-year-old child with HAV vaccination should be emphasized and a new strategy should be developed for the vaccination program to cater to the adolescents and young adults who are not immune, as well as for persons who are at a high risk for hepatitis A viral infection such as military personnel and hospital and day care center employees. Further, urgent hepatitis A vaccinations are also needed in patients with chronic liver diseases.

Epidemiologic Trends in Human Hepatitis A Virus Infection Stratified by Age between 2010 and 2018 in Cheonan, Korea

  • Jeon, Jae-Sik;Kim, Jae Kyung
    • 한국미생물·생명공학회지
    • /
    • 제48권4호
    • /
    • pp.564-568
    • /
    • 2020
  • Although studies on Hepatitis A virus (HAV) were crucial in the establishment of the HAV infection prevention programs, no systematic investigation into HAV has been conducted since 1999. We retrospectively analyzed the data between January 2010 to December 2018 from all the patients who underwent HAV antibody tests at the Dankook University Hospital Health Care Center. Data were collected from 56,204 individuals. Overall, 34,834 (62.0%) individuals from this cohort were positive for HAV antibodies and the annual rate of anti-HAV antibody positivity was highest in 2010 (68.5%) and lowest in 2013 (54.8%). The average decline in the antibody positivity rate was 0.62% per year, showing a statistically significant difference (p < 0.001). In the over 40s age group, anti-HAV antibody positivity rates decreased from 89% in 2010 to 64% in 2018 (p < 0.001), with an annual decrease of 3.1%. In the over 30s age group, it decreased from 48.2% in 2010 to 34.7% in 2018 (p < 0.001), with an annual decrease of 1.82%. This study shows that the antibody positivity rate is decreasing across age groups but given that HAV infection poses more significant risks in older patients it is important to expand the evaluations of the current and future antibody positivity rates for HAV in various age groups.

증상을 동반한 신생아 A형 간염 (Symptomatic Hepatitis A Virus Infection in a Newborn)

  • 진장용;홍예슬;이우령
    • Neonatal Medicine
    • /
    • 제17권1호
    • /
    • pp.123-126
    • /
    • 2010
  • 성인에서 A형 간염은 현증 감염이 대부분이지만, 소아에서는 무증상 또는 경한 증상을 보이는 경우가 많았다. 그동안 외국에서는 임신 및 분만 기간 동안에 발생한 A형 간염의 산모와 이로 인한 신생아 A형 간염에 대한 증례 보고가 드물지 않게 있었다. 국내에서는 20대와 30대의 젊은 성인에서 A형 간염에 대한 항체 양성률이 낮아지고 있는 가운데, 이들 산모들의 A형 간염에 대한 위험성이 증가하고 있는 상황이며, 아직까지 국내에서는 A형 간염에 이환된 신생아에 대한 증례 보고가 없었다. 이에 저자들은 A형 간염 산모로부터 이환된 것으로 보이는 급성 A형 간염 신생아를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.

Removal and Inactivation of Hepatitis A Virus during Manufacture of Urokinase from Human Urine

  • Kim, In-Seop;Park, Yong-Woon;Lee, Sung-Rae;Yong Kang;Lee, Kyung-Myung;Park, Dae-Han;Woo, Han-Sang;Lee, Soungmin
    • Biotechnology and Bioprocess Engineering:BBE
    • /
    • 제7권6호
    • /
    • pp.340-346
    • /
    • 2002
  • The purpose of the present study was to examine the efficacy and mechanism of the PAB (para-amino benzamidine) affinity column chromatography, Viresolve NFP virus filtration, pasteurization (60$\^{C}$ heat treatment for 10 h), and lyophilization steps employed in the manufacture of urokinase from human urine as regards the removal and/or inactivation of the hepatitis A virus (HAV). Samples from the relevant stages of the production process were spiked with HAV and subjected to scale-down processes mimicking the manufacture of urokinase Samples were collected at each step, immediately titrated using a 50% tissue culture infectious dose (TCID$\_$50/), and the virus reduction factors evaluated. PAB chromatography was found to be an effective step for removing HAV with a log reduction factor of 3.24. HAV infectivity was rarely detected in the urokinase fraction, while most of the HAV infectivity was recovered in the unbound and wash fractions. HAV was completely removed during the Viresolve NFP filtration with a log reduction factor of $\geq$ 4.60. Pasteurization was also found to be an effective step in inactivating HAV where the titers were reduced from an initial titer of 7.18 log$\_$10/ TCID$\_$50/ to undetectable levels within 10 h of treatment. The log reduction factor achieved during pasteurization was $\geq$ 4.76. Lyophilization revealed the lowest efficacy for inactivating HAV with a log reduction factor of 1.48. The cumulative log reduction factor was $\geq$ 14.08. Accordingly, these results indicate that the production process for urokinase exhibited a sufficient HAV reducing capacity to achieve a high margin of virus safety.